The estimated Net Worth of Jim Wassil is at least $26 Million dollars as of 3 September 2024. Jim Wassil owns over 10,000 units of Vaxcyte stock worth over $24,697,466 and over the last 4 years Jim sold PCVX stock worth over $1,287,660.
Jim has made over 26 trades of the Vaxcyte stock since 2021, according to the Form 4 filled with the SEC. Most recently Jim exercised 10,000 units of PCVX stock worth $24,200 on 3 September 2024.
The largest trade Jim's ever made was exercising 105,371 units of Vaxcyte stock on 23 December 2022 worth over $254,998. On average, Jim trades about 6,901 units every 41 days since 2021. As of 3 September 2024 Jim still owns at least 217,503 units of Vaxcyte stock.
You can see the complete history of Jim Wassil stock trades at the bottom of the page.
Jim's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., and Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: